The shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been pegged with a rating of Neutral by JP Morgan in its latest research note that was published on November 12, 2019. The Healthcare company has also assigned a $8 price target. JP Morgan wasn’t the only research firm that published a report of Teva Pharmaceutical Industries Limited, with other equities research analysts also giving their opinion on the stock. The stock had earned In-line rating from Evercore ISI Markets when it published its report on August 07, 2019. Morgan Stanley was of a view that TEVA is Underweight in its latest report on July 15, 2019. Credit Suisse thinks that TEVA is worth Neutral rating.
Amongst the analysts that rated the stock, 3 have recommended investors to sell it, 14 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $8.67. The price of the stock the last time has raised by 65.57% from its 52-Week high price while it is -50.27% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 56.23.
The shares of the company added by 0.90% during the trading session on Tuesday, reaching a low of $9.90 while ending the day at $10.05. During the trading session, a total of 4.87 million shares were traded which represents a 75.29% incline from the average session volume which is 19.7 million shares. TEVA had ended its last session trading at $9.96. Teva Pharmaceutical Industries Limited debt-to-equity ratio currently stands at 1.95, while its quick ratio hovers at 0.60 TEVA 52-week low price stands at $6.07 while its 52-week high price is $20.21.
The company in its last quarterly report recorded $0.56 earnings per share which is below the predicted by most analysts. The Teva Pharmaceutical Industries Limited generated 1.24 billion in revenue during the last quarter. In the second quarter last year, the firm recorded $0.57 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 1.79%. Teva Pharmaceutical Industries Limited has the potential to record 2.26 EPS for the current fiscal year, according to equities analysts.
Investment analysts at JP Morgan published a research note on July 23, 2019 where it informed investors and clients that Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is now rated as Overweight. Their price target on the stock stands at $16. Robert W. Baird also rated KPTI as Reiterated on July 05, 2019, with its price target of $25 suggesting that KPTI could surge by 17.52% from its current share price. Even though the stock has been trading at $19.18/share, analysts expect it to surge by 2.14% to reach $23.75/share. It started the day trading at $19.72 and traded between $19.085 and $19.59 throughout the trading session.
A look at its technical shows that KPTI’s 50-day SMA is 14.97 while its 200-day SMA stands at 9.17. The stock has a high of $19.26 for the year while the low is $3.92. The stock, however, witnessed a rise in its short on 12/13/19. Compared to previous close which recorded 11.11 M shorted shares, the short percentage went lower by -7.52%, as 10.27M TEVA shares were shorted. At the moment, only 21.55% of Karyopharm Therapeutics Inc. shares were sold short. The company’s average trading volume currently stands at 1.41M shares, which means that the short-interest ratio is just 7.87 days. Over the past seven days, the company moved, with its shift of 14.76%. Looking further, the stock has raised 93.29% over the past 90 days while it gained 223.27% over the last six months.
Consonance Capital Management LP meanwhile bought more KPTI shares in the recently filed quarter, changing its stake to $102,271,844 worth of shares.
Similarly, Palo Alto Investors LP decreased its Karyopharm Therapeutics Inc. shares by 7.98% during the recently filed quarter. After selling 4,842,150 shares in the last quarter, the firm now controls -420,113 shares of Karyopharm Therapeutics Inc. which are valued at $84,834,468. In the same vein, BlackRock Fund Advisors decreased its Karyopharm Therapeutics Inc. shares by during the most recent reported quarter. The firm bought 155,512 shares during the quarter which decreased its stakes to 4,286,588 shares and is now valued at $75,101,022. Following these latest developments, around 2.10% of Karyopharm Therapeutics Inc. stocks are owned by institutional investors and hedge funds.